Bacteria from the Bordetella genus are
responsible for respiratory infections in humans (Bordetella
pertussis and Bordetella parapertussis and whooping cough) and in
animals (Bordetella bronchiseptica and atrophic rhinitis and kennel
cough). The researches developed in our laboratory are aimed to
characterize the determinants involved in the pathogenicity of these
bacteria analyse immune responses induced in the host after
infection and after vaccination, surveillance of polymorphism of
clinical isolates and setting up of new prevention and new diagnosis
for whooping cough and other bordetellosis
I -
Bordetella pertussis VIRULENCE DETERMINANTS
Does adenylate cyclase-hemolysin toxin interact with a
receptor on eucaryotic cells ?
[N. Khelef, in collaboration with P.
Guermonprez and C. Leclerc]
We previously shown that adenylate
cyclase-hemolysin (AC-Hly) toxin, secreted by B. pertussis,
is responsible in vivo and in vitro of alveolar
macrophages death via apoptosis but is not cytotoxic for
epithelial cells. For this reason we made the hypothesis that
a specific receptor for AC-Hly exists on the macrophage
surface. In fact, using different specific antibodies we
recently showed that the integrin Mac-1 is the receptor of
AC-Hly. Since epithelial cells do not express Mac-1, they are
resistant to AC-Hly toxin.
What is the localisation of adenylate cyclase-hemolysin
inside macrophages or epithelial cells ? [N. Khelef in
collaboration with P. Gounon]
It was important using confocal microscopy
and immunofluorescence labelling what was the AC-Hly
localisation inside the macrophage. Our results show that
after fixation on its receptor AC-Hly enters the cell by
macropinocytosis. This mechanim is required for AC-Hly
cytotoxic activity.
II - PHYSIOPATHOLOGY OF BORDETELLA INFECTIONS
Interactions of Bordetella pertussis with human tracheal
epithelial cells [L. Bassinet, P. Gueirard in collaboration
with P. Gounon]
Epithelial cell plays a role in the
recrutment of inflammary cells via cytokines secretion. For
this reason our aim is to analyse which cytokines are secreted
by human tracheal epithelial cells infected by B. pertussis
or in contact with purified toxins or adhesins. Our
preliminary results show that B. pertussis strains
induce IL-6 secretion while there is no induction or
inhibition of secretion of IL-8.
Do Bordetella pertussis or Bordetella bronchiseptica
survive intracellularly ? In which cell ? [P. Gueirard, S.
Thiberge in collaboration with P. Ave, M. Huerre, AM. Balazuc
and G. Milon]
The study is performed in vivo using
our murine respiratory model and in vitro. Is the
target cell a dendritic leukocyte ? Our first results indicate
the recruitment of dendritic leucocytes in the pulmonary
parenchymus and bronchoalveolar fluid early after infection as
well as the presence of intracellular bacteria.
III - POLYMORPHISM OF BORDETELLA PERTUSSIS,
PARAPERTUSSIS, AND BRONCHISEPTICA ISOLATES
Is there a genetical drift in Bordetella pertussis
population over vaccinal pressure ? [C. Boursaux-Eude, F.
Rimlinger, C. Weber]
Analysis, by typing technique or sequencing of toxin
and adhesin structural genes, of isolates circulating in
France, a vaccinated country since more than thirty five
years with a whole-cell vaccine, confirmed that B.
pertussis isolates circulating before and after
introduction of generalized vaccination are different.
However, a precise analysis suggests that B.
pertussis population could vary regularly every
three years.
Analysis of isolates circulating in Japan, a
vaccinated country using acellular vaccines since twenty
years showed that circulating isolates are similar to
the vaccinal strain. Use of acellular vaccines does not
seem to induce a strong selection pressure. However, a
greater number of isolates has to be analysed before to
draw any conclusion.
We are currently analizing B. pertussis
isolates from Russia a country with a low vaccine
coverage.
Polymorphism structural gene encoding pertactin in
Bordetella pertussis, parapertussis and
bronchiseptica
We previously shown that PRN expressed by B.
pertussis, B. parapertussis and B.
bronchiseptica are very similar but do not induce a
cross reactive protective immunity. The differences
between the three proteins are located on two regions of
the PRN protein (I and II) containing repeated regions.
Analysis of several B. pertussis,
parapertussis and bronchiseptica PRN
indicates that B. pertussis PRN variation is
located on region I whereas B. bronchiseptica PRN
variation is mainly located on region II. This result
shows the importance of PRN region II for the induction
of protective immunity. One can suppose that variation
of this region could induce vaccine failure.
IV - WHOOPING COUGH PREVENTION
What is the prevalence of whooping cough in adults in
France ? [E. Njamkepo, A. Le Flèche, P. Gueirard in
collaboration with I. Parent (AMP), S. Gilberg (SFTG) and
Aventis-Pasteur and Aventis Pasteur-MSD]
In France, since several years a resurgence
of whooping cough is observed with infants contamined by
adolescents and adults. In order to confirm this epidemiology
we undertook with 80 general practitioners, a study to
determine the prevalence of whooping cough in adults, describe
the clinical symptoms during the disease and evaluate the
ability of biological diagnosis such as culture, PCR and
serology to diagnose the disease in adult. A prevalence of 32
% was found. All confirmed case were characterized by : a
higher frequency of work stops, cough with whoops PCR on
experations is a more sensitive diagnosis than culture.
Measurement of anti-pertussis toxin IgG and IgA by ELISA seems
also a very useful diagnosis.
Is Bordetella pertussis polymorphism affecting vaccine
efficacy ? [S. Thiberge in collaboration with GlaxoSmithKline
and Aventis-Pasteur Laboratories]
Our murine intranasal model, was used to
compare the ability of different whole cell and acellular
vaccines. Till now, all vaccines are able to induce a
protective immunity against infections due to different
variants.
Whooping cough and immunotherapy [E. Coëffier-Vicart, S.
Thiberge in collaboration with F. Nato and P. Lafaye]
The new epidemiology in countries using
generalized vaccination since many years is characterized by
an increase in new-born mortality (too young to be vaccinated)
contaminated by adolescents or adults whom immunity waned with
time. The use of specific antibodies able to neutralize toxins
and adhesins activities could be a useful tool to decrease
symptoms during infection and to stop transmission of the
bacteria. For these reason we tested the ability of different
antibodies to decrease symptoms after Bordetella
infections using our respiratory murine model.
V - BORDETELLA BRONCHISEPTICA HUMAN AND ANIMAL INFECTIONS
Bordetella bronchiseptica human and animal infections [P.
Gueirard, S. Thiberge, L. Guillemot in collaboration with C.
Barny]
B. bronchiseptica is a respiratory
pathogen for many mamals species, including human. In human,
B. bronchiseptica is considered as an opportunist
pathogen for immunodepressed patient or patient with
respiratory problems. We previously described that this
bacterium can induce chronic infections. We confirmed the
zoonotic character of this infection with two patients
contaminated with either infected rabbit or dog. Furthermore,
samples from dogs showed that the bacterium can be isolated on
vaccinated dogs.
Studies will continue because of the
increase of immunocompromised patients, absence of cross
protection of new pertussis vaccine, low efficacy of
veterinary vaccines and antibiotic resistances carried by this
bacterium.
VI - CENTRE NATIONAL DE REFERENCE
CNR [G. Coralie, P. Gueirard, E. Njamkepo, S. Thiberge]
The missions of this Centre is to confirm
the identification of Bordetella isolates collected in
France, to maintain the collection, to teach French
bacteriologists, to analyse isolates by Pulsed-Field-Gel
Electrophoresis, as well as the toxins and adhesins they
express, to set up sensitive and specific biological diagnosis
techniques and to be part of the National surveillance net,
RENACOQ, coordinated by the Ministery of Health.
VII - QUALITY INSURANCE
Quality Insurance [F. Fouque]
The set up of procedures and quality
insurance in the laboratory was pursued.
DISCLAIMER: All
information, data, and material contained, presented, or provided here is for
general information purposes only and is not to be construed as reflecting the
knowledge or opinions of the publisher, and is not to be construed or intended
as providing medical or legal advice. The decision whether or not to vaccinate
is an important and complex issue and should be made by you, and you alone, in
consultation with your health care provider.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
"What's the point of vaccination if it doesn't protect you from the unvaccinated?"
-- Sandy Gottstein
"Who gets to decide what the greater good is and how many will be sacrificed to it?"